Aptinyx Inc (NASDAQ:APTX) has been given an average rating of “Buy” by the seven analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $14.00.
A number of brokerages recently weighed in on APTX. Zacks Investment Research raised shares of Aptinyx from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a research note on Wednesday, March 27th. Cantor Fitzgerald reduced their target price on shares of Aptinyx from $18.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, March 22nd. BMO Capital Markets reaffirmed an “outperform” rating on shares of Aptinyx in a research note on Friday, March 22nd. Cowen reaffirmed a “buy” rating on shares of Aptinyx in a research note on Monday, June 10th. Finally, Svb Leerink began coverage on shares of Aptinyx in a research note on Thursday, June 20th. They issued an “outperform” rating and a $12.00 target price for the company.
In other Aptinyx news, Director Henry O. Gosebruch acquired 100,000 shares of Aptinyx stock in a transaction dated Wednesday, May 8th. The stock was bought at an average cost of $3.86 per share, for a total transaction of $386,000.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 8.47% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the company. Great West Life Assurance Co. Can acquired a new position in shares of Aptinyx during the 4th quarter worth about $40,000. Gabelli Funds LLC acquired a new position in shares of Aptinyx during the 1st quarter worth about $44,000. Alambic Investment Management L.P. acquired a new position in shares of Aptinyx during the 1st quarter worth about $87,000. Metropolitan Life Insurance Co. NY boosted its stake in shares of Aptinyx by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock worth $120,000 after buying an additional 5,652 shares during the last quarter. Finally, Barclays PLC boosted its stake in shares of Aptinyx by 87.1% during the 4th quarter. Barclays PLC now owns 9,323 shares of the company’s stock worth $154,000 after buying an additional 4,340 shares during the last quarter. Institutional investors own 58.37% of the company’s stock.
NASDAQ APTX traded down $0.02 on Thursday, reaching $3.34. The company had a trading volume of 253 shares, compared to its average volume of 276,763. The firm has a market cap of $111.08 million and a price-to-earnings ratio of -1.26. Aptinyx has a 1-year low of $2.88 and a 1-year high of $32.25. The stock’s fifty day moving average price is $3.35.
Aptinyx (NASDAQ:APTX) last announced its earnings results on Tuesday, May 14th. The company reported ($0.50) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.04). The company had revenue of $0.89 million during the quarter, compared to analyst estimates of $1.00 million. Aptinyx had a negative return on equity of 37.53% and a negative net margin of 1,166.40%. On average, sell-side analysts predict that Aptinyx will post -2.21 EPS for the current year.
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Featured Article: What is a capital gains distribution?
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.